Press Releases

2010/05/28 Insilico supplies bio-bricks for virtual liver

The human liver is a highly efficient and extremely complex organ. After all, thousands of different substances are channelled through this vital organ every day for processing. Systematic research is being carried out to determine just exactly what happens there, and Insilico Biotechnology is providing models and analyses particularly for degradation pathways.
read more

2010/04/26 Antibiotics & Co: Insilico and partners to improve biotech production

A veritable network specialist has become active in yet another network: the GenBioCom joint project financed by BMBF (Federal Ministry of Education and Research) is profiting from Insilico Biotechnology‘s know-how on bacterial metabolism and genome-based metabolic simulations. The ultimate goal is to improve and expand the commercial use of Actinomyces bacteria as producers of bioproducts and active agents.
read more

2010/03/09 Insilico: co-designer of innovative cell factory for fine chemicals

A new BMBF joint project to transfer systems biology research directly into practical applications is profiting from Insilico Biotechnology’s expertise. The goal is to make Pseudomonas bacterial strains fit for commercial use in the field of industrial biocatalysis. The project will run for three years, coordinated by BASF and financed with approx. EUR 5.5 million. Insilico Biotechnology is the second partner from industry, while all others are university research institutes, mostly from the region around Stuttgart.
read more

2010/02/03 Insilico banks on high-performance computing

Insilico Biotechnology is cooperating with HLRS, the High Performance Computing Center Stuttgart, in order to take computations for the fields of industrial and pharmaceutical biotechnology to new superior levels. The joint project, which is being funded by the German Federal Ministry of Economics and Technology, aims at developing methods for using thousands of computational cores simultaneously so that innovative predictions can be made much faster than today.
read more

2009/12/01 Harmless or lethal? Insilico Furthers Research on Fungal Infections

Candida albicans is a harmless yeast fungus – at least most of the time. However, if the immune system is weak, then the fungus normally found on everyone’s skin and mucous membranes can become a lethal threat. Insilico Biotechnology is participating in a joint project funded by the German Federal Ministry of Education and Research (BMBF), in which interactions between fungus and human host cells are to be studied on the molecular level with the aim of developing new strategies for the prevention, diagnosis and therapy of fungal infections.
read more

2008/12/30 Insilico joins industry collaboration on microbial genome research

Insilico Biotechnology AG enters a consortium of leading companies in the chemicals, pharmaceuticals and nutrition industries pooling forces on microbial genome research. Industry and BMBF will provide around 600 million Euros for white biotechnology over the next decade.
read more

2008/11/28 Insilico is building in silico cells for Evonik Industries

Insilico Biotechnology AG announces a multi-year collaboration with Evonik Industries, a global leader in systems-oriented development of industrial fermentations. The Stuttgart-based company provides its platform and expertise for building and simulating in silico bacterial strains.
read more

2008/01/22 Insilico expands collaboration with Kluyver Centre for Genomics of Industrial Fermentation

Insilico Biotechnology AG announces a continued collaboration with the Netherlands’ Kluyver Centre, a joint industry and academic consortium that applies genomics technology for improving industrial fermentation. The Stuttgart based company provides its new steady state and dynamic modeling and simulation platform for the set-up and analysis of predictive metabolic network models.
read more

2007/10/17 Threefold Promotion: Insilico and BioIndustry 2021

Insilico Biotechnology AG is partner in three out of five clusters belonging to the new research initiative entitled »BioIndustry 2021« which aims at meeting the oncoming challenges facing today’s society — first and foremost changes in climate followed by the ever increasing lack of resources — with innovative projects from the field of white biotechnology.

Insilico’s focus is on networking. Together with other partners from industry and research institutions, Insilico is playing an active role in BioIndustry 2021. The German Ministry of Education and Research (BMBF) is supporting this initiative with 60 million € in order to turn research ideas from the field of white biotechnology into products for marketing as soon as possible. The Ministry’s major goal here is to make Germany one of the most attractive sites in the world for biosciences.
read more

2007/08/21 Insilico is designing Formula One-type bacteria

Insilico Biotechnology AG in multi-year collaboration with Wacker Chemie AG to design high-performance bacterial strains

Insilico Biotechnology AG is set to become one of the partners in the GenoMik-Plus network. The Stuttgart-based company will provide the partners of the research consortium with network models and simulations of the bacterial metabolism. The objective is to develop high-performance bacterial strains that produce large amounts of useful substances.

2007/07/19 Virtual Liver Cells Optimize Drug Development

Insilico Biotechnology AG from Stuttgart with new funding for systems biology research from the German Federal Ministry of Education and Research (BMBF)

Since 2005, Insilico Biotechnology AG as an industrial partner in the federal HepatoSys competence network has been performing computer-based mapping and testing of liver cell metabolism. As a service provider in the systems biology sector, Insilico is responsible in particular for determining kinetic parameters using supercomputers. The aim is to model a »virtual liver cell« to enable physiological cell processes — such as the breakdown of drugs and toxic substances — to be followed »in silico«, i.e. on the computer. For the second project phase, this Stuttgart-based life science company is receiving Euro 250,000 of funding in the next three years.
read more

2006/10/09 Full Speed ahead for Biotech Process Development

Stuttgart-based Insilico Biotechnology AG launches initial bioscience simulations on Europe’s fastest vector processor

Since the start of October 2006, Insilico Biotechnology AG has been using Europe’s fastest vector computer for highly complex biotech process simulations. The high-performance computer centre at the University of Stuttgart (HLRS) enables this life science company to perform computing operations in a fraction of the time previously needed. The results are eagerly awaited.
read more

2006/07/18 Genedata and Insilico in Systems Biology Collaboration

Genedata and Insilico Biotechnology will work together using systems biology to support life science companies enhance their biotechnological production methods. The collaboration will combine Genedata’s computational systems for genomics data management and analysis with Insilico’s pathway simulation tools.
read more

Website Navigation